Refractory Metastatic Insulinoma Treated with Everolimus, Complicated by Cryptogenic Organizing Pneumonia

Charles J. Kim¹, Devon McKenzie², Joe K. Joseph¹, Yasemin Aytaman¹, Milay Luis Lam³, Lina Soni³ and Samy I. McFarlane^4,

¹Department of Medicine, State University of New York: Downstate Medical Center

²Department of Hematology and Oncology, State University of New York: Downstate Medical Center

³Department of Endocrinology, State University of New York: Downstate Medical Center

⁴Department of Medicine and Department of Endocrinology, State University of New York: Downstate Medical Center

Cite this paper:
Charles J. Kim, Devon McKenzie, Joe K. Joseph, Yasemin Aytaman, Milay Luis Lam, Lina Soni and Samy I. McFarlane. Refractory Metastatic Insulinoma Treated with Everolimus, Complicated by Cryptogenic Organizing Pneumonia. American Journal of Medical Case Reports. 2019; 7(7):125-132. doi: 10.12691/ajmcr-7-7-2

Abstract

Insulinoma is a rare neuroendocrine pancreatic islet cell tumor of which the majority are benign and solitary. Its estimated incidence is 2 to 4 cases per 1 million person-years. We report the case of an 82-year-old female who presented with metastatic insulinoma to the liver and retroperitoneal lymph nodes. It was diagnosed based on positive Whipple’s triad, elevated insulin, elevated C-peptide, and negative insulin auto-antibody. Her disease was initially managed with diazoxide 100 mg orally every 8 hours, octreotide LAR 30 mg intramuscularly every month, and sunitinib 12.5 mg orally three times a day. However, patient had recurrent symptoms and imaging consistent with worsened metastatic insulinoma; and thus, treatment was changed to everolimus 10 mg PO daily. Over the subsequent 10 months, the patient developed progressive shortness of breath and hypoxemia with and oxygen saturation (SpO2) of 89% on room air. Computerized tomography (CT) and lung biopsy were consistent with cryptogenic organizing pneumonia (COP) temporally associated with the initiation of everolimus. She was started on prednisone 1 mg/kg/day and within 48 hours, her symptoms and hypoxemia improved to SpO2 of 98-99% at room air and her repeat CT chest showed marked disease improvement. Given her good response with everolimus, it was continued in conjunction with the prednisone and to this day, patient has had a significant therapeutic response with normoglycemia and stable, well-controlled symptoms. This case is unique because to our knowledge, it is the first reported case of a patient with metastatic insulinoma complicated by the development of cryptogenic organizing pneumonia. It reaffirms the causal association between everolimus and cryptogenic organizing pneumonia that has been reported numerous times in literature. However, there has been no reported cases showing that the COP can be managed with prednisone concurrently with everolimus for the metastatic insulinoma without diminished clinical benefit. While pulmonary complications have been cited as reasons for discontinuation of everolimus therapy, our case report highlights the use of steroids as a viable therapeutic strategy that allows successful therapy with everolimus to be continued. In addition to presenting this case, we will also do a thorough review of the literature surrounding the available therapeutic options of metastatic insulinoma. This will include surgery, somatostatin analogs, antimicrobials, potassium channel activators, VEGF-A inhibitors, alkylating agents and mTOR inhibitors to provide a more in-depth picture of how we treat metastatic insulinoma.

Keywords:
Insulinoma cryptogenic organizing pneumonia everolimus

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma – incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991; 66: 711-719.
[2]	Hirshberg B, Livi A, Bartlett DL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 2000; 85: 3222-6.
[3]	Service, F. J., & Natt, N. (2000). The Prolonged Fast. The Journal of Clinical Endocrinology & Metabolism, 85(11), 3973-3974.
[4]	Service FJ. Hypoglycemic disorders. N Engl J Med. 1995; 332(17): 1144-52.
[5]	Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007; 48: 508-518.
[6]	Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol. 2005; 19: 783-798.
[7]	Su, A., Ke, N., Zhang, Y., Liu, X., Hu, W., Tian, B., & Zhang, Z. (2014). Is laparoscopic approach for pancreatic insulinomas safe? Results of a systematic review and meta-analysis. Journal of Surgical Research, 186(1), 126-134.
[8]	Mehrabi A, Fischer L, Hafezi M, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014; 43: 675-86.
[9]	Levy, M., & Topazian, M. (2011). Sp694 Ultrasound Guided Ethanol Ablation of Insulinomas: A New Treatment Option. Gastrointestinal Endoscopy, 73(4).
[10]	Jürgensen C., Schuppan D., Neser F., Ernstberger J., Junghans U., Stölzel U. EUS-guided alcohol ablation of an insulinoma. Gastrointestinal Endoscopy. 2006; 63(7): 1059-1062.
[11]	Deprez P. H., Claessens A., Borbath I., Gigot J. F., Maiter D. Successful endoscopic ultrasound-guided ethanol ablation of a sporadic insulinoma. Acta Gastroenterologica Belgica. 2008; 71: 333-337.
[12]	Doyle, M.E. Pharmacological agents that directly modulate insulin secretion. Pharmacol. Rev. 2003, 55, 105-131.
[13]	Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol. 2010; 6: 229-237.
[14]	Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997; 73(864): 640-641.
[15]	Plöckinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007; 21: 145-62.
[16]	Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, Morano S, et al. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res. 2006;65(3):120-5.
[17]	von Eyben FE, Grodum E, Gjessing HJ, Hagen C, Nielsen H. Metabolic remission with octreotide in patients with insulinoma. J Intern Med (1994) 235: 245-810.
[18]	Eriksson B., Renstrup J., Imam H., Öberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects. Annals of Oncology. 1997; 8(10): 1041-1044.
[19]	Tomassetti P, Migliori M, Gullo L. Slow‐release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93: 1468-1471.
[20]	Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40:56-68.
[21]	Lin, T., Leung, C., Nguyen, K. T., & Figlin, R. A. (2016). Mammalian target of rapamycin (mTOR) inhibitors in solid tumours. Clinical Pharmacist. Retrieved August 1, 2018, from https://www.pharmaceutical-journal.com/research/review-article/mammalian-target-of-rapamycin-mtor-inhibitors-in-solid-tumours/20200813.article?firstPass=false#comments_form.
[22]	Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6): 514-523.
[23]	Weiner SM, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature. Nephrol Dial Transplant 2007; 22: 3631.
[24]	Champion L, Stern M, Israël-Biet D, et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144: 505.
[25]	Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77: 1215.
[26]	White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182:396-403.
[27]	Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance). Matthew H. Kulke, Donna Niedzwiecki, Nathan R. Foster, Briant Fruth, Pamela L. Kunz, Hagen F. Kennecke, Edward M. Wolin, and Alan P. Venook. Journal of Clinical Oncology 2015 33: 15_suppl, 4005-4005.
[28]	Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor (PNET). Timothy J. Hobday, Jun Yin, Adam Pettinger, Jonathan R. Strosberg, Diane Lauren Reidy, Helen X. Chen, and Charles Erlichman. Journal of Clinical Oncology 2015 33: 15_suppl, 4096-4096.
[29]	Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-10.
[30]	Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501-13.
[31]	Chen J, Wang C, Han J, et al. Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther. 2013; 13: 737-743.
[32]	Demirkan B, Eriksson B. Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J. Gastroenterol. 2012; 23(5): 427-37.
[33]	Nazer L, Alnajjar T, Salah S, Khzouz J, Alfaqeer N, Qandeel M. Fatal case of cryptogenic organizing pneumonia associated with everolimus. Ann Saudi Med. 2014; 34(5): 437-439.
[34]	Bernard V, Lombard-Bohas C, Taquet MC, et al. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol 2013; 168: 665-674.